<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908776</url>
  </required_header>
  <id_info>
    <org_study_id>v216/6/2014</org_study_id>
    <nct_id>NCT02908776</nct_id>
  </id_info>
  <brief_title>MYocardial DAmage AND MIcrobiota STUDY</brief_title>
  <acronym>MYDA-MI</acronym>
  <official_title>Gut Flora Modulation for The Prevention of Pci-Related Myocardial Injury - A Randomized, Placebo Controlled, Double Blind, Investigator-Initiated, Single Centre, Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Filippo Neri General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MENDES S.A., Lugano, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit√† degli studi di Bologna, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Filippo Neri General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MYDA-MI study is a randomized, placebo controlled, double blind study performed in San
      Filippo Neri Hospital, Roma, Italy. The planned study duration is 18 months. The objectives
      are to assess the effects of pre-treatment with probiotic Ecoviesel on the incidence and
      magnitude of peri-procedural myocardial damage caused by coronary angioplasty in stable
      patients. 250 patients with chronic stable angina scheduled for a coronary angiography and
      possible ad hoc angioplasty will be randomized to receive pre-treatment with Ecoviesel
      sachets (each sachet contains 200 billions bacteria) or Placebo. The pre-treatment dosage
      will be 4 sachets of probiotic Ecoviesel or placebo for at least 2 weeks before the planned
      procedure. In patients undergoing angioplasty the same treatment will be continued for 4
      weeks after PCI with secondary outcome measures performed at the end of this second stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of abnormal c-TnI levels in patients undergoing coronary intervention</measure>
    <time_frame>within 24 hours from coronary angioplasty</time_frame>
    <description>Percentage of patients with plasma c-TnI&gt;99th percentile of normality at least one blood sample among those drawn at 6, 12 a 24 h post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak of c-TnI levels in patients undergoing coronary intervention</measure>
    <time_frame>within 24 hours from coronary angioplasty</time_frame>
    <description>peak plasma c-TnI concentration in blood samples drawn at 6, 12 a 24 h post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of contrast-induced renal dysfunction in all patients</measure>
    <time_frame>within 24 hours from coronary angioplasty</time_frame>
    <description>Percentage of patients with plasma creatinine&gt;25% from baseline in least one blood sample among those drawn at 6, 12 a 24 h post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-hospital incidence of major adverse cardiac events in patients undergoing coronary intervention</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Percentage of patients with in-hospital acute myocardial infarction, death or unplanned revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in hs-CRP in all patients after treatment phases</measure>
    <time_frame>within 30 days of the invasive procedure</time_frame>
    <description>Change in plasma hs-CRP concentration at any visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine metabolomics in all patients after treatment phases</measure>
    <time_frame>up to 30 days of the invasive procedure</time_frame>
    <description>Change in urine metabolomics at any visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Stable Angina</condition>
  <condition>Periprocedural Myocardial Damage</condition>
  <arm_group>
    <arm_group_label>Dietary supplement - Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sachets with inactive substance indistinguishable from Ecoviesel</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.</description>
    <arm_group_label>Dietary supplement - Probiotics</arm_group_label>
    <other_name>Ecoviesel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic stable angina scheduled for coronary angiography and possible ad
             hoc percutaneous coronary intervention

        Exclusion Criteria:

          -  Age &gt;75 y.o

          -  Diabetes requiring treatment

          -  Abnormal c-TnI level before angiography

          -  Immunodeficiency status

          -  Need for oral vitamin K antagonists

          -  Need for antibiotics

          -  Use of antibiotics or probiotics within 4 weeks of enrollment

          -  Cancer and diseases affecting 1 year prognosis

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Pristipino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Pristipino, MD</last_name>
    <phone>+39060633062504</phone>
    <email>pristipino.c@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Filippo Neri General Hospital</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Pristipino, MD</last_name>
      <phone>00390633061</phone>
      <email>pristipino.c@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Filippo Neri General Hospital</investigator_affiliation>
    <investigator_full_name>Christian Pristipino</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

